Crossmark

Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis

Crossref DOI link: https://doi.org/10.1186/s13075-022-02918-3

Published Online: 2022-10-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Koo, Bon San

Eun, Seongho

Shin, Kichul

Hong, Seokchan

Kim, Yong-Gil

Lee, Chang-Keun

Yoo, Bin

Oh, Ji Seon
Funding

Funding for this research was provided by:

National Research Foundation of Korea (NRF-2021R1C1C1009815)

Asan Institute for Life Sciences, Asan Medical Center (2021IP0047)

Ministry of Trade, Industry and Energy (20004927)

Korea Health Industry Development Institute (HR21C0198)
License Information

Text and Data Mining valid from 2022-10-14

Version of Record valid from 2022-10-14
More Information

Article History

Received: 11 November 2021

Accepted: 5 October 2022

First Online: 14 October 2022

Declarations

:

: Ethical approval of the KOBIO registry was obtained from the institutional review boards of all 38 participating institutions, including the Institutional Review Board of Inje University Seoul Paik Hospital (PAIK 2018–11-005).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below